{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "1915"
        },
        "variant_string_id": "LRRK2 I1915T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause PD via miRNA pathway impairment, leading to overproduction of E2F1/DP critical for pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines LRRK2's role in miRNA pathway deregulation and its link to E2F1/DP overproduction, which is central to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vivo EGFP reporter assays with let-7-binding sites monitor miRNA activity, and pathogenic LRRK2 variants (dLRRK(I1915T), hLRRK2(G2019S)) were tested for miRNA pathway interference.",
          "judgment": "Yes",
          "reasoning": "The miRNA pathway assay directly models the disease mechanism described in Step 1, as it evaluates LRRK2's impact on miRNA-regulated protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Variant Controls",
          "extracted_paper_info": "Genetic deletions (let-7), RNAi (LRRK2), and comparisons to wild-type proteins were used as controls.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic (e.g., dLRRK(I1915T)) and benign variants (e.g., genetic deletions) were tested as controls, satisfying variant control criteria."
        },
        {
          "step_name": "Step 4: Correlate OddsPath",
          "extracted_paper_info": "Pathogenic variants increased reporter expression compared to wild-type, with attenuation observed upon miRNA upregulation. Statistical analyses showed differential toxicity correlated with variant effects.",
          "judgment": "No",
          "reasoning": "The paper lacks explicit OddsPath calculation but provides robust statistical correlation between variant effects and miRNA pathway disruption."
        }
      ],
      "final_strength": {
        "type": "PS3_moderate",
        "description": "Functional evidence shows pathogenic variants (dLRRK(I1915T), hLRRK2(G2019S)) significantly disrupt miRNA pathway regulation, leading to E2F1/DP overproduction and PD pathogenesis. While OddsPath calculation is absent, the correlation with differential toxicity and attenuation upon miRNA upregulation meets ACMG criteria for moderate strength."
      }
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause PD via miRNA pathway impairment, leading to overproduction of E2F1/DP critical for pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly defines LRRK2's role in miRNA pathway deregulation and its link to E2F1/DP overproduction, which is central to PD pathogenesis."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "In vivo EGFP reporter assays with let-7-binding sites monitor miRNA activity, and pathogenic LRRK2 variants (dLRRK(I1915T), hLRRK2(G2019S)) were tested for miRNA pathway interference.",
          "judgment": "Yes",
          "reasoning": "The miRNA pathway assay directly models the disease mechanism described in Step 1, as it evaluates LRRK2's impact on miRNA-regulated protein synthesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3: Variant Controls",
          "extracted_paper_info": "Genetic deletions (let-7), RNAi (LRRK2), and comparisons to wild-type proteins were used as controls.",
          "judgment": "Yes",
          "reasoning": "Known pathogenic (e.g., hLRRK2(G2019S)) and benign variants (e.g., genetic deletions) were tested as controls, satisfying variant control criteria."
        },
        {
          "step_name": "Step 4: Correlate OddsPath",
          "extracted_paper_info": "Pathogenic variants increased reporter expression compared to wild-type, with attenuation observed upon miRNA upregulation. Statistical analyses showed differential toxicity correlated with variant effects.",
          "judgment": "No",
          "reasoning": "The paper lacks explicit OddsPath calculation but provides robust statistical correlation between variant effects and miRNA pathway disruption."
        }
      ],
      "final_strength": {
        "type": "PS3_moderate",
        "description": "Functional evidence shows pathogenic variants (dLRRK(I1915T), hLRRK2(G2019S)) significantly disrupt miRNA pathway regulation, leading to E2F1/DP overproduction and PD pathogenesis. While OddsPath calculation is absent, the correlation with differential toxicity and attenuation upon miRNA upregulation meets ACMG criteria for moderate strength."
      }
    }
  ]
}